Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:GOSS NASDAQ:MLYS NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$21.81-3.8%$16.74$9.60▼$23.24$2.92B1.471.41 million shs1.30 million shsGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.20 million shs4.24 million shsMLYSMineralys Therapeutics$37.10-0.2%$17.92$8.24▼$39.20$2.46B-0.292.59 million shs1.27 million shsTARSTarsus Pharmaceuticals$49.36-4.8%$48.63$30.23▼$59.76$2.08B0.81646,954 shs1.23 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%+38.65%+20.83%+73.10%+28.37%GOSSGossamer Bio0.00%+17.69%+76.53%+170.31%+275.52%MLYSMineralys Therapeutics0.00%+6.61%+155.51%+175.84%+215.48%TARSTarsus Pharmaceuticals0.00%-14.35%-8.95%+19.54%+48.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$21.81-3.8%$16.74$9.60▼$23.24$2.92B1.471.41 million shs1.30 million shsGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.20 million shs4.24 million shsMLYSMineralys Therapeutics$37.10-0.2%$17.92$8.24▼$39.20$2.46B-0.292.59 million shs1.27 million shsTARSTarsus Pharmaceuticals$49.36-4.8%$48.63$30.23▼$59.76$2.08B0.81646,954 shs1.23 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%+38.65%+20.83%+73.10%+28.37%GOSSGossamer Bio0.00%+17.69%+76.53%+170.31%+275.52%MLYSMineralys Therapeutics0.00%+6.61%+155.51%+175.84%+215.48%TARSTarsus Pharmaceuticals0.00%-14.35%-8.95%+19.54%+48.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.08Buy$32.7049.93% UpsideGOSSGossamer Bio 3.00Buy$8.50145.66% UpsideMLYSMineralys Therapeutics 2.83Moderate Buy$43.5017.25% UpsideTARSTarsus Pharmaceuticals 2.71Moderate Buy$66.6735.06% UpsideCurrent Analyst Ratings BreakdownLatest GOSS, CNTA, TARS, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/11/2025MLYSMineralys TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $50.009/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.009/8/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/5/2025TARSTarsus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.008/29/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.008/28/2025MLYSMineralys TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $43.008/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M426.36N/AN/A$3.05 per share7.15GOSSGossamer Bio$114.70M6.86N/AN/A$0.13 per share26.62MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ATARSTarsus Pharmaceuticals$182.95M11.39N/AN/A$5.87 per share8.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest GOSS, CNTA, TARS, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.3210.1110.12GOSSGossamer Bio6.704.404.40MLYSMineralys TherapeuticsN/A15.1215.12TARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%GOSSGossamer Bio81.23%MLYSMineralys Therapeutics84.46%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%GOSSGossamer Bio6.70%MLYSMineralys Therapeutics33.24%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableMLYSMineralys Therapeutics2866.29 million44.26 millionOptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableGOSS, CNTA, TARS, and MLYS HeadlinesRecent News About These CompaniesWoodline Partners LP Trims Stake in Tarsus Pharmaceuticals, Inc. $TARS1 hour ago | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 4.1% on Insider SellingSeptember 13 at 11:43 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 4.1% After Insider SellingSeptember 13 at 2:19 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 27,116 SharesSeptember 12 at 5:36 PM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comAdage Capital Partners GP L.L.C. Acquires New Shares in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comBaird Financial Group Inc. Decreases Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comCormorant Asset Management LP Sells 100,000 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comCutter Capital Management LP Acquires 92,500 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comAlly Bridge Group NY LLC Sells 45,212 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 5, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Time to Buy?September 4, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Frazier Life Sciences Management L.P.September 4, 2025 | marketbeat.comNorthern Trust Corp Grows Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 3, 2025 | marketbeat.comGhisallo Capital Management LLC Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 2, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Position Increased by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.com5,284 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by FORA Capital LLCSeptember 1, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Invests $36.88 Million in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comJump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 29, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGOSS, CNTA, TARS, and MLYS Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$21.81 -0.86 (-3.79%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$21.66 -0.15 (-0.71%) As of 09/12/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Gossamer Bio NASDAQ:GOSS$3.46 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.49 +0.03 (+0.87%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$37.10 -0.06 (-0.16%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$36.50 -0.60 (-1.62%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Tarsus Pharmaceuticals NASDAQ:TARS$49.36 -2.51 (-4.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$49.34 -0.02 (-0.03%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
